EUCTR2016-003093-40-DE进行中（未招募）1 期
Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end point (PROBE) study - the CARAVAGGIO study - CARAVAGGIO
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Consecutive patients with a newly diagnosed, objectively confirmed:
- •Symptomatic or unsuspected, proximal lower-limb DVT or
- •Symptomatic PE or
- •Unsuspected PE in a segmental or more proximal pulmonary artery.
- •2) Any type of cancer (other than basal-cell or squamous-cell carcinoma
- •of the skin, primary brain tumor or known intracerebral metastases and
- •acute leukemia) that meets at least one of the following:
- •Active cancer defined as diagnosis of cancer within six months before
- •the study inclusion, or receiving treatment for cancer at the time of
- •inclusion or any treatment for cancer during 6 months prior to
- •randomization, or recurrent locally advanced or metastatic cancer.
- •Cancer diagnosed within 2 years before the study inclusion (history of
- •3) Signed and dated informed consent, available before the start of any
- •specific trial procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 818
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 350
排除标准
- •1) Age <18 years
- •2) ECOG Performance Status III or IV;
- •3) Life expectancy of less than 6 months;
- •Related to anticoagulant treatment:
- •4) Administration of therapeutic doses of LMWH, fondaparinux, or
- •unfractionated heparin (UFH) for more than 72 hours before
- •randomization;
- •5) 3 or more doses of a vitamin K antagonist before randomization;
- •6) Thrombectomy, vena cava filter insertion, or thrombolysis used to
- •manage the index episode;
- •7) Iindication for anticoagulant treatment for a disease other than the
- •index VTE episode;
- •8) Concomitant use of strong inhibitors or inducers of both cytochrome
- •P-450 3A4 and P-Glycoprotein (see Appendix 1);
- •Related to bleeding risk:
- •9) Concomitant thienopyridine therapy (clopidogrel, prasugrel, or
- •ticagrelor) or aspirin over 165 mg daily or dual antiplatelet therapy;
- •10) Active bleeding or high risk of bleeding contraindicating
- •anticoagulant treatment
- •11) Recent (in the last 1 month prior to randomization) brain, spinal
- •or ophthalmic surgery
- •12) Hemoglobin level lower than 8 g/dL (5.0 mmol/L) or platelet count
- •<75x109/L or history of heparin-induced thrombocytopenia;
- •13) Creatinine clearance < 30 ml /min based on the Cockcroft Gault
- •14) Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine
- •aminotransferase level 3 times or more and/or bilirubin level 2 times or
- •more higher the upper limit of the normal range;
- •15) Uncontrolled hypertension (systolic BP> 180 mm Hg or diastolic BP
- •> 100 mm Hg despite antihypertensive treatment);
- •Standard criteria:
- •16) Bacterial endocarditis;
- •17) Hypersensitivity to the study drugs or to any of their excipients;
- •18) Patients participation in other pharmaco therapeutic program with
- •an experimental therapy that is known to effect the coagulation system.
- •19) Women of childbearing potential (WOCBP) who do not practice a
- •medically accepted highly effective contraception during the trial and
- •one month beyond. Highly effective contraception methods are:
- •a. combined (estrogen and progestogen containing) hormonal
- •contraception associated with inhibition of ovulation
- •b. progestogen-only hormonal contraception associated with inhibition
- •of ovulation
- •c. intrauterine device (IUD)
- •d. intrauterine hormone-releasing system (IUS)
- •e. bilateral tubal occlusion
- •f. vasectomized partner
- •g. sexual abstinence ;
- •20) Pregnancy, or breast feeding
- •21) Any condition that, as judged by the investigator, would place the
- •subject at increased risk of harm if he/she participated in the study.
研究者
相似试验
进行中（未招募）
1 期
Apixaban for the treatment of venous thromboembolism in patients with cancerEUCTR2016-003093-40-PTFONDAZIONE FADOI1,200
进行中（未招募）
1 期
Apixaban for the treatment of venous thromboembolism in patients with cancerVenous thromboembolism in cancer patientsMedDRA version: 21.1Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 100000004866EUCTR2016-003093-40-ITFONDAZIONE FADOI1,168
进行中（未招募）
1 期
Apixaban for the treatment of venous thromboembolism in patients with cancerVenous thromboembolism in cancer patientsEUCTR2016-003093-40-NLFONDAZIONE FADOI70
已完成
3 期
Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (probe) study - the Caravaggio studyNL-OMON50094Fondazione FADOI Italian Federation of Hospital Internists180
进行中（未招募）
1 期
Apixaban for the treatment of venous thromboembolism in patients with cancerEUCTR2016-003093-40-GBFONDAZIONE FADOI1,168